Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer

doi:10.4251/wjgo.v15.i11.1913

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1363)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

695

Figures (1-3)

130

Tables (1-4)

Sum=964

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

101

Download

250

Sum=351

Nov 15, 2023 (publication date) through May 20, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Nov 15, 2023; 15(11): 1913-1924
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1913

Open in New Tab Full Size Figure Download Figure

Figure 1 Tumor location and progression-free survival and overall survival. A: Progression-free survival; B: Overall survival. OS: Overall survival; PFS: Progression-free survival; HR: Hazard ratio; 95%CI: 95% confidence interval.

Open in New Tab Full Size Figure Download Figure

Figure 2 Serum gamma-glutamyl transferase and progression-free survival and overall survival. A: Progression-free survival; B: Overall survival. GGT: Gamma-glutamyl transferase; OS: Overall survival; PFS: Progression-free survival; HR: Hazard ratio; 95%CI: 95% confidence interval.

Open in New Tab Full Size Figure Download Figure

Figure 3 Overall survival by tumor histological grade, performance status, and bilirubin. A: Tumor histological grade; B: Performance status; C: Bilirubin. PS: Performance status; OS: Overall survival; HR: Hazard ratio; 95%CI: 95% confidence interval.

Citation: Mullin G, Sternschuss M, Landman Y, Sulkes A, Brenner B. Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer. World J Gastrointest Oncol 2023; 15(11): 1913-1924
URL: https://www.wjgnet.com/1948-5204/full/v15/i11/1913.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i11.1913